Keywords: schering, ag, zevalin, cleared, ec, european, commission

Schering AG's Zevalin cleared by EC

Article | 26 January 2004

The European Commission has granted marketing authorization to Germany's Schering AG for its radioimmunotherapy product Zevalin (ibritumomab tiuxetan). The product ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Schering Ag

Biogen Idec

Go to company listing

Related Drugs

Ibritumomab Tiuxetan

Zevalin

Rituxan

Rituximab

Go to drug listing